Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
David Elkins
Pharma
Bristol Myers counters Revlimid generics with 3 new launches
As Revlimid generics take their toll, BMS feels confident it can shepherd its roster of new drugs toward more than $25 billion in sales by 2029.
Fraiser Kansteiner
Oct 26, 2022 9:37am
With onset of generics, sales of BMS' Revlimid are fading fast
Apr 29, 2022 9:53am
Bristol bumps Lynch, recruits Novartis vet for post-merger team
Jun 5, 2019 11:16am
Celgene CEO Alles to bag $28M if he departs after BMS merger
Feb 27, 2019 12:04pm
Celgene exec shakeup continues as J&J vet Elkins signs on as CFO
Jun 1, 2018 10:29am
